It remains far from clear whether the new surprise billing rule goes far enough to fix the problem of insurers having too much power in disputes.
Subscribe today for full access
to all of these articles.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.
The most recent congressional effort to pass LDT legislation may prove to be the one that finally comes to fruition.
A briefing on how labs should prepare for the inevitable end of the PHE after more than two years of unprecedented relief.
The relief package agreed to on April 4 appears to have become a collateral victim of a politically incendiary issue regarding immigration.
Legislation would require Medicare to cover genomic cancer testing and follow-up screening for those with a family history of cancer.